PATENT CLAIM ANALYSIS

Application Number: 15926812
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "367000"]

Abstract:
A method for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof comprising administering to said subject an effective amount of (6R)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole or pharmaceutically acceptable salt thereof, wherein said subject is a treatment responder. In certain embodiments, said subject is a subject with definite amyotrophic lateral sclerosis, a subject with amyotrophic lateral sclerosis symptom onset duration of less than about 18 months, a subject with a high level of serum creatinine, a subject with concomitant riluzole administration and combinations thereof.

Claim (Index 34):
The method of  claim 32 , wherein the subject further has diagnostic criteria selected from the group consisting of an ALSFRS-R score of greater than 36.0, a pre-study progression rate greater than or equal to 0.8 points per month, a percentage predicted relaxed (slow) vital capacity (SVC) of less than or equal to 102.0, an ALSFRS-R fine motor domain score of greater than 10.0 points, ALSFRS-R bulbar domain score or greater than 9.0 points, an ALSFRS-R gross motor domain score of greater than 8.0 points, an abnormal neurological exam of the tongue, an abnormal neurological exam of the pharynx, larynx and swallowing, an abnormal neurological exam of the lower extremities, an abnormal neurological exam of the upper extremities, an abnormal neurological exam of the triceps, an abnormal neurological exam of the muscle mass and bulk, an abnormal neurological exam of the bicep, an abnormal neurological exam, a diastolic blood pressure of greater than 82.0 mmHg, a systolic blood pressure of less than or equal to 117.0 mmHg, a phosphorous value of less than or equal to 1.090 \u03bcmol/L, a platelet count of less than or equal to 248.0\u00d710 9  cells/L, a lactate dehydrogenase value of less than or equal to 161.0 U/L, a triglyceride level of less than or equal to 1.4 mmol/L, a uric acid level of greater than 320.0 .mu.mol/L, a gamma-glutamyltransferase (GGT) level of greater than 37.0 U/L, a total bilirubin level of less than or equal to 6.0 \u03bcmol/L, a urine pH of less than or equal to 5.5, and any combination thereof.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 90.0
- Lexical Diversity: 1.66102
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15492832', '14194558', '12048890', '14878581', '15889714']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8017285067528085
- 35 USC 102 Novelty (BERT): 0.6512831175752576
- Combined Prediction Score: 0.7866839678350535
- Mean Citation Score: 454.606416
- Max Citation Score: 674.796
- Similarity Product: 572.7417090711593

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test